Clinical and Experimental Nephrology

, Volume 12, Issue 2, pp 126–131 | Cite as

Relationship between serum 1,25-dihydroxyvitamin D and mortality in patients with pre-dialysis chronic kidney disease

  • Daijo Inaguma
  • Hiroshi Nagaya
  • Kazuhiro Hara
  • Miho Tatematsu
  • Hibiki Shinjo
  • Sachiyo Suzuki
  • Tomoko Mishima
  • Kei Kurata
Original Article



It is known that vitamin D has many functions besides involvement in calcium metabolism. It has recently been recognized that vitamin D deficiency is associated with mortality, especially in cardiovascular disease (CVD). Vitamin D deficiency is common in end-stage renal disease, but develops from the early stage of chronic kidney disease (CKD). So we investigated whether the serum level of the activated form of vitamin D (1,25-dihydroxyvitamin D) affected mortality in patients with CKD stages 3 and 4.


Between January 1, 1995, and June 30, 2006 we measured serum 1,25-dihydroxyvitamin D In 226 patients with CKD stages 3 and 4 and classified the results into two groups depending on whether the level was below (group I) or above (group II) 20 pg/ml. We ended the follow-up period on December 31, 2006. We compared all-cause and cardiovascular mortality between the two groups. We also examined predictors of mortality by using Cox proportional regression analysis.


Two-hundred and twenty-six patients (67 men and 159 women, mean age 67.0) were registered in this study, and groups 1 and 2 comprised 84 and 142 patients, respectively. During the follow-up period 43 patients died. CVD was the major cause of death, followed by infectious disease. The Kaplan–Meier survival curve revealed that all-cause mortality was significantly higher in group I, but a significant difference between CVD mortality in the two groups was not demonstrated. By Cox proportional regression analysis, group I was related to all-cause mortality, but this was not proved to be an independent predictor.


The results suggested that serum level of 1,25-dihydroxyvitamin D was associated with all-cause mortality in patients with CKD stages 3 and 4.


1,25-Dihydroxyvitamin D Chronic kidney disease Pre-dialysis 


  1. 1.
    Slatopolsky E, Brown A, Dusso A. Pathogenesis of secondary hyperparathyroidism. Kidney Int. 1999;73:S14–9.CrossRefGoogle Scholar
  2. 2.
    Andress DL. Vitamin D in chronic kidney disease: a systemic role for selective vitamin D receptor activation. Kidney Int. 2006;69:33–43.PubMedCrossRefGoogle Scholar
  3. 3.
    Levin A, Bakris GL, Molitch M, Smulders M, Tian J, Williams LA, Andress DL. Prevalence of abnormal serum vitamin D, PTH, calcium, and phosphorus in patients with chronic kidney disease: results of the study to evaluate early kidney disease. Kidney Int. 2007;71:31–8.PubMedCrossRefGoogle Scholar
  4. 4.
    Fraga C, Blanco M, Vigo E, Segura C, Garcia-Caballero T, Perez-Fernandez R. Ontogenesis of the vitamin D receptor in rat heart. Histochem Cell Biol. 2002;117:547–50.PubMedCrossRefGoogle Scholar
  5. 5.
    Suda T, Jimi E, Nakamura I, Takahashi N. Role of 1 alpha, 25-dihydroxyvitamin D3 in osteoclast differentiation and function. Methods Enzymol. 1997;282:223–35.PubMedCrossRefGoogle Scholar
  6. 6.
    Major GC, Alarie F, Dore J, Phouttama S, Tremblay A. Supplementation with calcium + vitamin D enhances the beneficial effect of weight loss on plasma lipid and lipoprotein concentrations. Am J Clin Nutr. 2007;85:54–9.PubMedGoogle Scholar
  7. 7.
    Imazeki I, Matsuzaki J, Tsuji K, Nishimura T. Immunomodulating effect of vitamin D3 derivatives on type-1 cellular immunity. Biomed Res. 2006;27:1–9.PubMedCrossRefGoogle Scholar
  8. 8.
    Remuzzi A. Vitamin D, insulin resistance, and renal disease. Kidney Int. 2007;71:96–8.PubMedCrossRefGoogle Scholar
  9. 9.
    Levin A, Li YC. Vitamin D and its analogues: do they protect against cardiovascular disease in patients with kidney disease? Kidney Int. 2005;68:1973–81.PubMedCrossRefGoogle Scholar
  10. 10.
    Luong KVQ, Nguyen LTH. Vitamin D and cardiovascular disease. Curr Med Chem. 2006;13:2443–7.PubMedCrossRefGoogle Scholar
  11. 11.
    Levey AS, Bosch JP, Lewis JB, Greene T, Rodgers N, Roth D. A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Ann Intern Med. 1999;130:461–70.PubMedGoogle Scholar
  12. 12.
    National Kidney Foundation. K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Dis. 2002;39:S1–226.CrossRefGoogle Scholar
  13. 13.
    Imai E, Horio M, Nitta K, Yamagata K, Iseki K, Hara S, Ura N, Kiyohara Y, Hirakata H, Watanabe T, Moriyama T, Ando Y, Inaguma D, Narita I, Iso H, Wakai K, Yasuda Y, Tsukamoto Y, Ito S, Makino H, Hishida A, Matsuo S. Estimation of glomerular filtration rate by the MDRD study equation modified for Japanese patients with chronic kidney disease. Clin Exp Nephrol. 2007;11:41–50.PubMedCrossRefGoogle Scholar
  14. 14.
    Haussler MR, Whitfield GK, Haussler CA, Hsieh JC, Thompson PD, Selznick SH, Dominquez CE, Jurutka PW. The nuclear vitamin D receptor: biological and molecular regulatory properties revealed. J Bone Miner Res. 1998;13:325–49.PubMedCrossRefGoogle Scholar
  15. 15.
    O’Connell TD, Simpson RU. Immunochemical identification of the 1,25-dihydroxyvitamin D3 receptor protein in human heart. Cell Biol Int. 1996;20:621–4.PubMedCrossRefGoogle Scholar
  16. 16.
    Sandgren ME, Bronnegard M, DeLuca HF. Tissue distribution of the 1,25-dihydroxyvitamin D3 receptor in the male rat. Biochem Biophys Res Commun. 1991;181:611–6.PubMedCrossRefGoogle Scholar
  17. 17.
    Cardus A, Parisi E, Gallego C, Aldea M, Fernandez E, Valdivielso JM. 1,25-Dihydroxyvitamin D3 stimulates vascular smooth muscle cell proliferation through a VEGF-mediated pathway. Kidney Int. 2006;69:1377–84.PubMedGoogle Scholar
  18. 18.
    Chonchol M, Scragg R. 25-Hydroxyvitamin D, insulin resistance, and kidney function in the third national health and nutrition examination survey. Kidney Int. 2006;71:134–9.PubMedCrossRefGoogle Scholar
  19. 19.
    Zittermann A, Schleithoff SS, Tenderich G, Berthold HK, Korfer R, Stehle P. Low vitamin D status: a contributing factor in the pathogenesis of congestive heart failure? J Am Coll Cardiol. 2003;41:105–12.PubMedCrossRefGoogle Scholar
  20. 20.
    Schleithoff SS, Zittermann A, Tenderich G, Berthold HK, Stehle P, Koerfer R. Vitamin D supplementation improves cytokine profiles in patients with congestive heart failure: a double-blind, randomized, placebo-controlled trial. Am J Clin Nutr. 2006;83:754–9.PubMedGoogle Scholar
  21. 21.
    Bishop JE, Collins ED, Okamura WH, Norman AW. Profile of ligand specificity of the vitamin D binding protein for 1 alpha, 25-dihydroxyvitamin D3 and its analogs. J Bone Miner Res. 1994;9:1277–88.PubMedCrossRefGoogle Scholar
  22. 22.
    Guoth M, Murgia A, Smith RM, Prystowsky MB, Cooke NE, Haddad JG. Cell surface vitamin D-binding protein (GC-globulin) is acquired from plasma. Endocrinology. 1990;127:2313–21.PubMedCrossRefGoogle Scholar
  23. 23.
    Teng M, Wolf M, Lowrie E, Ofsthun N, Lazarus JM, Thadhani R. Survival of patients undergoing hemodialysis with paricalcitol or calcitriol therapy. N Engl J Med. 2003;349:446–56.PubMedCrossRefGoogle Scholar
  24. 24.
    Shoji T, Shinohara K, Kimoto E, Emoto M, Tahara H, Koyama H, Inaba M, Fukumoto S, Ishimura E, Miki T, Tabata T, Nishizawa Y. Lower risk for cardiovascular mortality in oral 1α-hydroxy vitamin D3 users in a haemodialysis population. Nephrol Dial Transplant. 2004;19:179–84.PubMedCrossRefGoogle Scholar

Copyright information

© Japanese Society of Nephrology 2008

Authors and Affiliations

  • Daijo Inaguma
    • 1
  • Hiroshi Nagaya
    • 1
  • Kazuhiro Hara
    • 1
  • Miho Tatematsu
    • 1
  • Hibiki Shinjo
    • 1
  • Sachiyo Suzuki
    • 1
  • Tomoko Mishima
    • 1
  • Kei Kurata
    • 1
  1. 1.Department of Nephrology and RheumatologyTosei General HospitalSetoJapan

Personalised recommendations